Search

Your search keyword '"Akilov, O."' showing total 112 results
Start Over Author "Akilov, O."
112 results on '"Akilov, O."'

24. Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

Author

Hodak, E., Sherman, S., Papadavid, E., Bagot, M., Querfeld, C., Quaglino, P., Prince, H.M., Ortiz-Romero, P.L., Stadler, R., Knobler, R., Guenova, E., Estrach, T., Patsatsi, A., Leshem, Y.A., Prague-Naveh, H., Berti, E., Alberti-Violetti, S., Cowan, R., Jonak, C., Nikolaou, V., Mitteldorf, C., Akilov, O., Geskin, L., Matin, R., Beylot-Barry, M., Vakeva, L., Sanches, J.A., Servitje, O., Weatherhead, S., Wobser, M., Yoo, J., Bayne, M., Bates, A., Dunnill, G., Marschalko, M., Buschots, A.M., Wehkamp, U., Evison, F., Hong, E., Amitay-Laish, I., Stranzenbach, R., Vermeer, M., Willemze, R., Kempf, W., Cerroni, L., Whittaker, S., Kim, Y.H., Scarisbrick, J.J., Cutaneous Lymphoma Int Consortium, HUS Inflammation Center, Clinicum, and Helsinki University Hospital Area

Subjects
medicine.medical_specialty, Skin Neoplasms, EUROPEAN-ORGANIZATION, SOCIETY, Physical examination, Dermatology, GUIDELINES, CLASSIFICATION, Cutaneous lymphoma, Cutaneous patch, 030207 dermatology & venereal diseases, 03 medical and health sciences, Mycosis Fungoides, 0302 clinical medicine, International Prognostic Index, Biopsy, SEZARY-SYNDROME, medicine, Humans, COMPUTED-TOMOGRAPHY, Prospective Studies, Stage (cooking), RESPONSE CRITERIA, Neoplasm Staging, Body surface area, Mycosis fungoides, medicine.diagnostic_test, business.industry, CONSORTIUM, Prognosis, medicine.disease, 3121 General medicine, internal medicine and other clinical medicine, SURVIVAL, Lymph Nodes, Radiology, business, TASK-FORCE
Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2020
Full Text
View/download PDF

25. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E. Sherman, S. Papadavid, E. Bagot, M. Querfeld, C. Quaglino, P. Prince, H. M. Ortiz-Romero, P. L. and Stadler, R. Knobler, R. Guenova, E. Estrach, T. and Patsatsi, A. Leshem, Y. A. Prague-Naveh, H. Berti, E. and Alberti-Violetti, S. Cowan, R. Jonak, C. Nikolaou, V and Mitteldorf, C. Akilov, O. Geskin, L. Matin, R. and Beylot-Barry, M. Vakeva, L. Sanches, J. A. Servitje, O. and Weatherhead, S. Wobser, M. Yoo, J. Bayne, M. Bates, A. and Dunnill, G. Marschalko, M. Buschots, A. M. Wehkamp, U. and Evison, F. Hong, E. Amitay-Laish, I Stranzenbach, R. and Vermeer, M. Willemze, R. Kempf, W. Cerroni, L. and Whittaker, S. Kim, Y. H. Scarisbrick, J. J. Cutaneous Lymphoma Int Consortium

Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2021

26. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P. Prince, H. M. Cowan, R. Vermeer, M. and Papadavid, E. Bagot, M. Servitjie, O. Berti, E. Guenova, E. Stadler, R. Querfeld, C. Busschots, A. M. Hodak, E. and Patsatsi, A. Sanches, J. Maule, M. Yoo, J. Kevin, M. and Fava, P. Ribero, S. Zocchi, L. Rubatto, M. Fierro, M. T. Wehkamp, U. Marshalko, M. Mitteldorf, C. Akilov, O. Ortiz-Romero, P. Estrach, T. Vakeva, L. Enz, P. A. and Wobser, M. Bayne, M. Jonak, C. Rubeta, M. Forbes, A. and Bates, A. Battistella, M. Amel-Kashipaz, R. Vydianath, B. Combalia, A. Georgiou, E. Hauben, E. Hong, E. K. and Jost, M. Knobler, R. Amitay-Laish, I. Miyashiro, D. and Cury-Martins, J. Martinez, X. Muniesa, C. Prag-Naveh, H. and Stratigos, A. Nikolaou, V. Quint, K. Ram-Wolff, C. and Rieger, K. Stranzenbach, R. Szepesi, A. Alberti-Violetti, S. and Felicity, E. Cerroni, L. Kempf, W. Whittaker, S. and Willemze, R. Kim, Y. Scarisbrick, J. J.

Abstract

Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%

Published
2021

27. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, Scarisbrick, JJ, Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, and Scarisbrick, JJ

Abstract

BACKGROUND: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS: In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS: The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS: Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.

Published
2021

28. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, Scarisbrick, JJ, Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, and Scarisbrick, JJ

Abstract

BACKGROUND: Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. OBJECTIVES: To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. METHODS: A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. RESULTS: PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (≥ 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (≥ 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. CONCLUSIONS: Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients w

Published
2021

30. Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

Author

Quaglino, P., primary, Prince, H.M., additional, Cowan, R., additional, Vermeer, M., additional, Papadavid, E., additional, Bagot, M., additional, Servitjie, O., additional, Berti, E., additional, Guenova, E., additional, Stadler, R., additional, Querfeld, C., additional, Busschots, A.M., additional, Hodak, E., additional, Patsatsi, A., additional, Sanches, J., additional, Maule, M., additional, Yoo, J., additional, Kevin, M., additional, Fava, P., additional, Ribero, S., additional, Zocchi, L., additional, Rubatto, M., additional, Fierro, M.T., additional, Wehkamp, U., additional, Marshalko, M., additional, Mitteldorf, C., additional, Akilov, O., additional, Ortiz‐Romero, P., additional, Estrach, T., additional, Vakeva, L., additional, Enz, P.A., additional, Wobser, M., additional, Bayne, M., additional, Jonak, C., additional, Rubeta, M., additional, Forbes, A., additional, Bates, A., additional, Battistella, M., additional, Amel‐Kashipaz, R., additional, Vydianath, B., additional, Combalia, A., additional, Georgiou, E., additional, Hauben, E., additional, Hong, E.K., additional, Jost, M., additional, Knobler, R., additional, Amitay‐Laish, I., additional, Miyashiro, D., additional, Cury‐Martins, J., additional, Martinez, X., additional, Muniesa, C., additional, Prag‐Naveh, H., additional, Stratigos, A., additional, Nikolaou, V., additional, Quint, K., additional, Ram‐Wolff, C., additional, Rieger, K., additional, Stranzenbach, R., additional, Szepesi, Á., additional, Alberti‐Violetti, S., additional, Felicity, E., additional, Cerroni, L., additional, Kempf, W., additional, Whittaker, S., additional, Willemze, R., additional, Kim, Y., additional, and Scarisbrick, J.J., additional

Published
2021
Full Text
View/download PDF

31. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project

Author

Garg, A. Neuren, E. Cha, D. Kirby, J.S. Ingram, J.R. Jemec, G.B.E. Esmann, S. Thorlacius, L. Villumsen, B. Marmol, V.D. Nassif, A. Delage, M. Tzellos, T. Moseng, D. Grimstad, Ø. Naik, H. Micheletti, R. Guilbault, S. Miller, A.P. Hamzavi, I. van der Zee, H. Prens, E. Kappe, N. Ardon, C. Kirby, B. Hughes, R. Zouboulis, C.C. Nikolakis, G. Bechara, F.G. Matusiak, L. Szepietowski, J. Glowaczewska, A. Smith, S.D. Goldfarb, N. Daveluy, S. Avgoustou, C. Giamarellos-Bourboulis, E. Cohen, S. Soliman, Y. Brant, E.G. Akilov, O. Sayed, C. Tan, J. Alavi, A. Lowes, M.A. Pascual, J.C. Riad, H. Fisher, S. Cohen, A. Paek, S.Y. Resnik, B. Ju, Q. Wang, L. Strunk, A.

Abstract

Background: A needs assessment for patients with hidradenitis suppurativa (HS) will support advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. Objective: To evaluate unmet needs from the perspective of HS patients. Methods: Prospective multinational survey of patients between October 2017 and July 2018. Results: Before receiving a formal HS diagnosis, 63.7% (n = 827) of patients visited a physician ≥5 times. Mean delay in diagnosis was 10.2 ± 8.9 years. Patients experienced flare daily, weekly, or monthly in 23.0%, 29.8%, and 31.1%, respectively. Most (61.4% [n = 798]) rated recent HS-related pain as moderate or higher, and 4.5% described recent pain to be the worst possible. Access to dermatology was rated as difficult by 37.0% (n = 481). Patients reported visiting the emergency department and hospital ≥5 times for symptoms in 18.3% and 12.5%, respectively. An extreme impact on life was reported by 43.3% (n = 563), and 14.5% were disabled due to disease. Patients reported a high frequency of comorbidities, most commonly mood disorders. Patients were dissatisfied with medical or procedural treatments in 45.9% and 34.6%, respectively. Limitations: Data were self-reported. Patients with more severe disease may have been selected. Conclusion: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address. © 2019 American Academy of Dermatology, Inc.

Published
2020

32. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project

Author

Garg, A. (Amit), Neuren, E. (Erica), Cha, D. (Denny), Kirby, J.S. (Joslyn S.), Ingram, J.R. (John R.), Jemec, G.B.E. (Gregor), Esmann, S., Thorlacius, L. (Linnea), Villumsen, B. (Bente), Marmol, V.D. (Véronique del), Nassif, A. (Aude), Delage, M. (Maia), Tzellos, T. (Thrasivoulos), Moseng, D. (Dagfinn), Grimstad, Ø. (Øystein), Naik, H. (Haley), Micheletti, R. (Robert), Guilbault, S. (Sandra), Miller, A.P. (Angie Parks), Hamzavi, I., Zee, H.H. (Hessel) van der, Prens, E.P. (Errol), Kappe, N. (Naomi), Ardon, C. (Christine), Kirby, B. (Brian), Hughes, R. (Rosalind), Zouboulis, C.C. (Christos C.), Nikolakis, G. (Georgios), Bechara, F.G. (Falk G.), Matusiak, L., Szepietowski, J. (Jacek), Glowaczewska, A. (Amelia), Smith, S.D. (Saxon D.), Goldfarb, N. (Noah), Daveluy, S. (Steven), Avgoustou, C. (Christina), Giamarellos-Bourboulis, E. (Evangelos), Cohen, S. (Steven), Soliman, Y. (Yssra), Brant, E.G. (Elena Gonzalez), Akilov, O. (Oleg), Sayed, C. (Christopher), Tan, J. (Jerry), Alavi, A. (Afsaneh), Lowes, M.A. (Michelle A.), Pascual, J.C. (José Carlos), Riad, H., Fisher, S. (Shani), Cohen, A. (Arnon), Paek, S.Y. (So Yeon), Resnik, B. (Barry), Ju, Q. (Qiang), Wang, L. (Lanqi), Strunk, A. (Andrew), Garg, A. (Amit), Neuren, E. (Erica), Cha, D. (Denny), Kirby, J.S. (Joslyn S.), Ingram, J.R. (John R.), Jemec, G.B.E. (Gregor), Esmann, S., Thorlacius, L. (Linnea), Villumsen, B. (Bente), Marmol, V.D. (Véronique del), Nassif, A. (Aude), Delage, M. (Maia), Tzellos, T. (Thrasivoulos), Moseng, D. (Dagfinn), Grimstad, Ø. (Øystein), Naik, H. (Haley), Micheletti, R. (Robert), Guilbault, S. (Sandra), Miller, A.P. (Angie Parks), Hamzavi, I., Zee, H.H. (Hessel) van der, Prens, E.P. (Errol), Kappe, N. (Naomi), Ardon, C. (Christine), Kirby, B. (Brian), Hughes, R. (Rosalind), Zouboulis, C.C. (Christos C.), Nikolakis, G. (Georgios), Bechara, F.G. (Falk G.), Matusiak, L., Szepietowski, J. (Jacek), Glowaczewska, A. (Amelia), Smith, S.D. (Saxon D.), Goldfarb, N. (Noah), Daveluy, S. (Steven), Avgoustou, C. (Christina), Giamarellos-Bourboulis, E. (Evangelos), Cohen, S. (Steven), Soliman, Y. (Yssra), Brant, E.G. (Elena Gonzalez), Akilov, O. (Oleg), Sayed, C. (Christopher), Tan, J. (Jerry), Alavi, A. (Afsaneh), Lowes, M.A. (Michelle A.), Pascual, J.C. (José Carlos), Riad, H., Fisher, S. (Shani), Cohen, A. (Arnon), Paek, S.Y. (So Yeon), Resnik, B. (Barry), Ju, Q. (Qiang), Wang, L. (Lanqi), and Strunk, A. (Andrew)

Abstract

Background: A needs assessment for patients with hidradenitis suppurativa (HS) will support advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. Objective: To evaluate unmet needs from the perspective of HS patients. Methods: Prospective multinational survey of patients between October 2017 and July 2018. Results: Before receiving a formal HS diagnosis, 63.7% (n = 827) of patients visited a physician ≥5 times. Mean delay in diagnosis was 10.2 ± 8.9 years. Patients experienced flare daily, weekly, or monthly in 23.0%, 29.8%, and 31.1%, respectively. Most (61.4% [n = 798]) rated recent HS-related pain as moderate or higher, and 4.5% described recent pain to be the worst possible. Access to dermatology was rated as difficult by 37.0% (n = 481). Patients reported visiting the emergency department and hospital ≥5 times for symptoms in 18.3% and 12.5%, respectively. An extreme impact on life was reported by 43.3% (n = 563), and 14.5% were disabled due to disease. Patients reported a high frequency of comorbidities, most commonly mood disorders. Patients were dissatisfied with medical or procedural treatments in 45.9% and 34.6%, respectively. Limitations: Data were self-reported. Patients with more severe disease may have been selected. Conclusion: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address.

Published
2020
Full Text
View/download PDF

36. An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study

Author

Molloy, K. Jonak, C. Sherida, F. J. Woei-A-Ji, H. and Guenova, E. Busschots, A. M. Bervoets, A. Hauben, E. and Knobler, R. Porkert, S. Fassnacht, C. Cowan, R. and Papadavid, E. Beylot-Barry, M. Berti, E. Violetti, S. Alberti Estrach, T. Matin, R. Akilov, O. Vakeva, L. and Prince, M. Bates, A. Bayne, M. Wachsmuch, R. Wehkamp, U. and Marschalko, M. Servitje, O. Turner, D. Weatherhead, S. and Wobser, M. Sanches, J. Antonio Mckay, P. Klemke, D. and Howles, A. Yoo, J. Evison, F. Scarisbrick, J.

Published
2019

37. T-cell receptor rearrangements in the skin and blood of patients in the PROCLIPI study: detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients

Author

Wehkamp, U. Whittaker, S. Servitje, O. Berti, E. and Querfeld, C. Bagot, M. Stadler, R. Stranzenbach, R. and Marschalko, M. Busschots, A. -M. Jost, M. Sanches, J. and Ortiz-Romero, P. Estrach, T. Vakeva, L. Jonak, C. and Akilov, O. Hodak, E. Mitteldorf, C. Bates, A. and Beylot-Barry, M. Cowan, R. Pujol, R. Matin, R. and Papadavid, E. Quaglino, P. Vermeer, M. Kempf, W. Kim, Y. and Scarisbrick, J. PROCLIPI Investigators

Published
2019

38. 样肉芽肿和 Sézary 综合征患者生活质量研究

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei‐A‐Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2020
Full Text
View/download PDF

39. A study of quality of life in people with mycosis fungoides and Sézary syndrome

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei‐A‐Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2020
Full Text
View/download PDF

40. The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-Life Clinical Data

Author

Amitay-Laish, I, primary, Guenova, E, additional, Ortiz-Romero, P, additional, Vico-Alonso, C, additional, Rozati, S, additional, Geskin, L, additional, Nikolaou, V, additional, Papadavid, E, additional, Barzilai, A, additional, Pavlovsky, L, additional, Didkovsky, E, additional, Naveh, H, additional, Akilov, O, additional, and Hodak, E, additional

Published
2020
Full Text
View/download PDF

41. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( PROCLIPI ) study

Author

Molloy, K., primary, Jonak, C., additional, Woei‐A‐Jin, F.J.S.H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot‐Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Sanches, J.A., additional, McKay, P., additional, Klemke, D., additional, Peng, C., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2019
Full Text
View/download PDF

42. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)

Author

Horwitz, S.M., primary, Scarisbrick, J., additional, Prince, H.M., additional, Whittaker, S., additional, Duvic, M., additional, Kim, Y.H., additional, Quaglino, P., additional, Zinzani, P.L., additional, Bechter, O., additional, Eradat, H., additional, Pinter-Brown, L., additional, Akilov, O., additional, Geskin, L., additional, Sanches, J., additional, Ortiz-Romero, P., additional, Lisano, J., additional, Brown, L., additional, Palanca-Wessels, M.C., additional, Gautam, A., additional, Bunn, V., additional, Little, M., additional, and Dummer, R., additional

Published
2019
Full Text
View/download PDF

43. PS1063 RESULTS OF PIVOTAL PHASE 2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Author

Pemmaraju, N., primary, Lane, A., additional, Sweet, K., additional, Stein, A., additional, Vasu, S., additional, Rizzieri, D., additional, Wang, E., additional, Duvic, M., additional, Spence, S., additional, Shemesh, S., additional, Brooks, C., additional, Bergstein, I., additional, Chen, J., additional, McDonald, P., additional, Sloan, J.M., additional, Rosenblat, T., additional, Akilov, O., additional, Lancet, J., additional, Kantarjian, H., additional, and Konopleva, M., additional

Published
2019
Full Text
View/download PDF

44. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, Willemze, R, Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, and Willemze, R

Abstract

BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.

Published
2019

45. T-cell receptor rearrangements in the skin and blood of patients in the PROCLIPI study: detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients

Author

Wehkamp, U., primary, Whittaker, S., additional, Servitje, O., additional, Berti, E., additional, Querfeld, C., additional, Bagot, M., additional, Stadler, R., additional, Stranzenbach, R., additional, Marschalko, M., additional, Busschots, A.-M., additional, Jost, M., additional, Sanches, J., additional, Ortiz-Romero, P., additional, Estrach, T., additional, Vakeva, L., additional, Jonak, C., additional, Akilov, O., additional, Hodak, E., additional, Mitteldorf, C., additional, Bates, A., additional, Beylot-Barry, M., additional, Cowan, R., additional, Pujol, R., additional, Matin, R., additional, Papadavid, E., additional, Quaglino, P., additional, Vermeer, M., additional, Kempf, W., additional, Kim, Y., additional, and Scarisbrick, J., additional

Published
2019
Full Text
View/download PDF

46. An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study

Author

Molloy, K., primary, Jonak, C., additional, Sherida, F.J., additional, Woei-A-Ji, H., additional, Guenova, E., additional, Busschots, A.M., additional, Bervoets, A., additional, Hauben, E., additional, Knobler, R., additional, Porkert, S., additional, Fassnacht, C., additional, Cowan, R., additional, Papadavid, E., additional, Beylot-Barry, M., additional, Berti, E., additional, Alberti Violetti, S., additional, Estrach, T., additional, Matin, R., additional, Akilov, O., additional, Vakeva, L., additional, Prince, M., additional, Bates, A., additional, Bayne, M., additional, Wachsmuch, R., additional, Wehkamp, U., additional, Marschalko, M., additional, Servitje, O., additional, Turner, D., additional, Weatherhead, S., additional, Wobser, M., additional, Antonio Sanches, J., additional, McKay, P., additional, Klemke, D., additional, Howles, A., additional, Yoo, J., additional, Evison, F., additional, and Scarisbrick, J., additional

Published
2019
Full Text
View/download PDF

47. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Author

Molloy, K., Jonak, C., Woei‐A‐Jin, F.J.S.H., Guenova, E., Busschots, A.M., Bervoets, A., Hauben, E., Knobler, R., Porkert, S., Fassnacht, C., Cowan, R., Papadavid, E., Beylot‐Barry, M., Berti, E., Alberti Violetti, S., Estrach, T., Matin, R., Akilov, O., Vakeva, L., and Prince, M.

Subjects
SEZARY syndrome, MYCOSIS fungoides, QUALITY of life, LACTATE dehydrogenase, LYMPHOMAS, SHAME
Abstract

Summary: Background: Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common cutaneous T‐cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching and disfigurement. Aim: To identify factors associated with poorer health‐related quality of life (HRQoL) in patients newly diagnosed with MF/SS. Methods: Patients enrolled into Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI; an international observational study in MF/SS) had their HRQoL assessed using the Skindex‐29 questionnaire. Skindex‐29 scores were analysed in relation to patient‐ and disease‐specific characteristics. Results: The study population consisted of 237 patients [60·3% male; median age 60 years, (interquartile range 49–70)], of whom 179 had early MF and 58 had advanced MF/SS. In univariate analysis, HRQoL, as measured by Skindex‐29, was worse in women, SS, late‐stage MF, those with elevated lactate dehydrogenase, alopecia, high modified Severity Weighted Assessment Tool and confluent erythema. Linear regression models only identified female gender (β = 8·61; P = 0·003) and alopecia (β = 9·71, P = 0·02) as independent predictors of worse global HRQoL. Item‐level analysis showed that the severe impairment in symptoms [odds ratio (OR) 2·14, 95% confidence interval (CI) 1·19–3·89] and emotions (OR 1·88, 95% CI 1·09–3·27) subscale scores seen in women was caused by more burning/stinging, pruritus, irritation and greater feelings of depression, shame, embarrassment and annoyance with their diagnosis of MF/SS. Conclusions: HRQoL is significantly more impaired in newly diagnosed women with MF/SS and in those with alopecia. As Skindex‐29 does not include existential questions on cancer, which may cause additional worry and distress, a comprehensive validated cutaneous T‐cell lymphoma‐specific questionnaire is urgently needed to more accurately assess disease‐specific HRQoL in these patients. What's already known about this topic? Cross‐sectional studies of mixed populations of known and newly diagnosed patients with mycosis fungoides (MF)/Sézary syndrome (SS) have shown significant impairment in health‐related quality of life (HRQoL).Previous studies on assessing gender‐specific differences in HRQoL in MF/SS are conflicting.More advanced‐stage disease and pruritus is associated with poorer HRQoL in patients with MF/SS. What does this study add? This is the first prospective study to investigate HRQoL in a homogenous group of newly diagnosed patients with MF/SS.In patients newly diagnosed with MF/SS, HRQoL is worse in women and in those with alopecia and confluent erythema.MF/SS diagnosis has a multidimensional impact on patient HRQoL, including a large burden of cutaneous symptoms, as well as a negative impact on emotional well‐being. Linked Comment:Talpur. Br J Dermatol 2020; 182:541–542. Plain language summary available online [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, J.J., primary, Quaglino, P., additional, Prince, H.M., additional, Papadavid, E., additional, Hodak, E., additional, Bagot, M., additional, Servitje, O., additional, Berti, E., additional, Ortiz‐Romero, P., additional, Stadler, R., additional, Patsatsi, A., additional, Knobler, R., additional, Guenova, E., additional, Child, F., additional, Whittaker, S., additional, Nikolaou, V., additional, Tomasini, C., additional, Amitay, I., additional, Prag Naveh, H., additional, Ram‐Wolff, C., additional, Battistella, M, additional, Alberti‐Violetti, S., additional, Stranzenbach, R., additional, Gargallo, V., additional, Muniesa, C., additional, Koletsa, T., additional, Jonak, C., additional, Porkert, S., additional, Mitteldorf, C., additional, Estrach, T., additional, Combalia, A., additional, Marschalko, M., additional, Csomor, J., additional, Szepesi, A., additional, Cozzio, A., additional, Dummer, R., additional, Pimpinelli, N., additional, Grandi, V., additional, Beylot‐Barry, M., additional, Pham‐Ledard, A., additional, Wobser, M., additional, Geissinger, E., additional, Wehkamp, U., additional, Weichenthal, M., additional, Cowan, R., additional, Parry, E., additional, Harris, J., additional, Wachsmuth, R., additional, Turner, D., additional, Bates, A., additional, Healy, E., additional, Trautinger, F., additional, Latzka, J., additional, Yoo, J., additional, Vydianath, B., additional, Amel‐Kashipaz, R., additional, Marinos, L., additional, Oikonomidi, A., additional, Stratigos, A., additional, Vignon‐Pennamen, M.‐D., additional, Battistella, M., additional, Climent, F., additional, Gonzalez‐Barca, E., additional, Georgiou, E., additional, Senetta, R., additional, Zinzani, P., additional, Vakeva, L., additional, Ranki, A., additional, Busschots, A.‐M., additional, Hauben, E., additional, Bervoets, A., additional, Woei‐A‐Jin, F.J.S.H., additional, Matin, R., additional, Collins, G., additional, Weatherhead, S., additional, Frew, J., additional, Bayne, M., additional, Dunnill, G., additional, McKay, P., additional, Arumainathan, A., additional, Azurdia, R., additional, Benstead, K., additional, Twigger, R., additional, Rieger, K., additional, Brown, R., additional, Sanches, J.A., additional, Miyashiro, D., additional, Akilov, O., additional, McCann, S., additional, Sahi, H., additional, Damasco, F.M., additional, Querfeld, C., additional, Folkes, A., additional, Bur, C., additional, Klemke, C.‐D., additional, Enz, P., additional, Pujol, R., additional, Quint, K., additional, Geskin, L., additional, Hong, E., additional, Evison, F., additional, Vermeer, M., additional, Cerroni, L., additional, Kempf, W., additional, Kim, Y., additional, and Willemze, R., additional

Published
2018
Full Text
View/download PDF

50. PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY

Author

Prince, H.M., primary, Dummer, R., additional, Whittaker, S., additional, Horwitz, S., additional, Duvic, M., additional, Scarisbrick, J., additional, Quaglino, P., additional, Zinzani, P.L., additional, Wolter, P., additional, Sanches, J., additional, Ortiz-Romero, P., additional, Akilov, O., additional, Geskin, L., additional, Huen, A., additional, Wang, Y., additional, Palanca-Wessels, M.C., additional, Richhariya, A., additional, Feliciano, J., additional, Zhu, Y., additional, Lin, H., additional, Liu, Y., additional, Little, M., additional, Zagadailov, E., additional, Dalal, M., additional, and Kim, Y.H., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results